Adverum Biotechnologies (LSE:0HA3) - Cotización, noticias y análisis

Resumen de acción 0HA3

Adverum Biotechnologies, Inc. es una empresa en fase clínica que desarrolla candidatos a productos de terapia génica para tratar enfermedades oculares.

Acerca de la empresa

0HA3 fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Recompensas

Análisis de riesgos

Los accionistas han sido diluidos sustancialmente en el último año

Se prevé que los beneficios disminuyan una media de 6.2% al año durante los próximos 3 años.

Alta volatilidad del precio de la acción en los últimos 3 meses

No tiene ingresos significativos ($4M)

+ 1 riesgos adicionales

Competidores de Adverum Biotechnologies, Inc.

4basebio

AIM:4BB

UK£132.5m

Oxford Biomedica

LSE:OXB

UK£202.0m

Bioventix

AIM:BVXP

UK£240.1m

NIOX Group

AIM:NIOX

UK£273.9m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Adverum Biotechnologies
Historical stock prices
Current Share Price	US$11.19
52 Week High	US$29.50
52 Week Low	US$7.40
Beta	0.79
1 Month Change	-26.62%
3 Month Change	32.81%
1 Year Change	13.90%
3 Year Change	-87.70%
5 Year Change	-79.65%
Change since IPO	-84.01%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	0HA3	GB Biotechs	Mercado GB
7D	-6.5%	-2.3%	-0.7%
1Y	13.9%	-29.4%	-1.8%

Rentabilidad vs. Industria: 0HA3 superó al sector UK Biotechs , que obtuvo un rendimiento del -27.8% el año pasado.

Rentabilidad vs. Mercado: 0HA3 superó al mercado UK, que obtuvo un rendimiento del -5.4% el año pasado.

Volatilidad de los precios

Is 0HA3's price volatile compared to industry and market?
0HA3 volatility
0HA3 Average Weekly Movement	19.9%
Biotechs Industry Average Movement	7.5%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	11.5%
10% least volatile stocks in GB Market	2.6%

Precio estable de las acciones: 0HA3ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: 0HA3(20%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de los valores de UK.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2006	121	Laurent Fischer	adverum.com

Adverum Biotechnologies, Inc. es una empresa en fase clínica que desarrolla productos de terapia génica candidatos para el tratamiento de enfermedades oculares. Su principal producto candidato es el ixoberogene soroparvovec (ADVM-022), un candidato a terapia génica de inyección intravítrea única utilizado para el tratamiento de pacientes con degeneración macular húmeda asociada a la edad y edema macular diabético, que se encuentra en ensayos clínicos de fase 2. La empresa está desarrollando ADVM-062 (AAV.7m8-L-opsina), un nuevo producto de terapia génica candidato para el tratamiento de la monocromía de conos azules mediante una única inyección intravítrea.

Resumen de fundamentos de Adverum Biotechnologies, Inc.

¿Cómo se comparan los beneficios e ingresos de Adverum Biotechnologies con su capitalización de mercado?
Estadísticas fundamentales de 0HA3
Capitalización bursátil	US$235.36m
Beneficios(TTM)	-US$117.16m
Ingresos (TTM)	US$3.60m

65.4x

Ratio precio-ventas (PS)

-2.0x

Ratio precio-beneficio (PE)

¿Está 0HA3 sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de 0HA3
Ingresos	US$3.60m
Coste de los ingresos	US$77.68m
Beneficio bruto	-US$74.08m
Otros gastos	US$43.09m
Beneficios	-US$117.16m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-5.65
Margen bruto	-2,057.67%
Margen de beneficio neto	-3,254.58%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado 0HA3 a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción 0HA3

Recompensas

Análisis de riesgos

Competidores de Adverum Biotechnologies, Inc.

AIM:4BB

UK£132.5m

LSE:OXB

UK£202.0m

AIM:BVXP

UK£240.1m

AIM:NIOX

UK£273.9m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Adverum Biotechnologies, Inc. announced that it has received $127.5 million in funding from a group of investors

Adverum Biotechnologies, Inc. Announces Positive Preliminary Efficacy and Safety Data from Luna Phase 2 Trial of Ixo-Cov in Patients with Wet AMD

Adverum Biotechnologies, Inc. Announces Stipulation and Agreement of Settlement

Adverum Biotechnologies, Inc. announced that it expects to receive $127.5 million in funding from a group of investors

Adverum Biotechnologies, Inc. Appoints Romuald Corbau as Chief Scientific Officer and Member of Executive Committee

Adverum Biotechnologies Receives a Letter from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

Recent updates

Adverum Biotechnologies, Inc. announced that it has received $127.5 million in funding from a group of investors

Adverum Biotechnologies, Inc. Announces Positive Preliminary Efficacy and Safety Data from Luna Phase 2 Trial of Ixo-Cov in Patients with Wet AMD

Adverum Biotechnologies, Inc. Announces Stipulation and Agreement of Settlement

Adverum Biotechnologies, Inc. announced that it expects to receive $127.5 million in funding from a group of investors

Adverum Biotechnologies, Inc. Appoints Romuald Corbau as Chief Scientific Officer and Member of Executive Committee

Adverum Biotechnologies Receives a Letter from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

Adverum Biotechnologies, Inc. Appoints C. David Nicholson to the Board of Directors

Adverum Biotechnologies, Inc. Announces Positive Aflibercept Protein Level Data from the Luna Phase 2 Trial

Adverum Biotechnologies, Inc. Appoints R. Andrew Andy Ramelmeier as Chief Technology Officer

Adverum Biotechnologies, Inc. Appoints R. Andrew Andy Ramelmeier as Chief Technology Officer

Adverum Biotechnologies, Inc. Completes Enrollment of Phase 2 LUNA Trial in Wet AMD

Adverum Biotechnologies Receives Nasdaq Notice on Regained Compliance with Minimum Bid Price Requirement

Adverum Biotechnologies, Inc. Announces Resignation of Richard Beckman as Chief Medical Officer

Adverum Biotechnologies, Inc. Receives Approval from the Listing Qualifications Department of Nasdaq to Transfer the Listing of Common Stock from Nasdaq Global Market to Nasdaq Capital Market

Adverum Biotechnologies, Inc. Presents Nonclinical Data in Support of Ixo-vec’s Phase 2 Clinical Development at ASGCT 2023 Annual Meeting

Adverum Biotechnologies, Inc. Appoints Linda Rubinstein as Chief Financial Officer

Adverum Biotechnologies, Inc. Announces New Data from the OPTIC Study Treating Wet Age-Related Macular Degeneration

Adverum Biotechnologies Announces First Subject Dosed with Ixo-vec in the Phase 2 LUNA Trial for the Treatment of Wet Age-Related Macular Degeneration

Adverum Biotechnologies, Inc. Presents Best-Corrected Visual Acuity and Central Subfield Thickness Analyses After A Single IVT Injection of ADVM-022 (Ixo-vec) in the OPTIC Study in Wet AMD

Adverum Biotechnologies Announces Upcoming Data Presentation at ASRS 2022

Adverum Biotechnologies, Inc. Completes IND Amendment and Prepares to Initiate Phase 2 LUNA Trial of ADVM-022 in Wet AMD

Adverum Biotechnologies, Inc.(NasdaqGM:ADVM) dropped from Russell 2000 Dynamic Index

Adverum Biotechnologies, Inc. Presents Three-Year Aflibercept Protein Expression and Improvement in Anatomic Outcomes After A Single IVT Injection of ADVM-022 in the Optic Study in Wet AMD

Adverum Biotechnologies, Inc. Announces Executive Changes

Adverum Biotechnologies Announces New Data At the Macula Society's 2022 Annual Meeting

Adverum Biotechnologies Presents Research Pipeline Data Supporting Utility of Its Proprietary Platform and AAV.7m8 Capsid in Ocular Gene Therapy

Adverum Biotechnologies, Inc. Presents Data At American Society of Gene and Cell Therapy Further Supporting Phase 2 Development Plans for ADVM-022

Adverum Biotechnologies, Inc. Presents Additional Efficacy and Safety Data from the Optic Trial of ADVM-022 in Wet AMD At the ARVO 2022 Annual Meeting

High number of new directors

Adverum Biotechnologies, Inc. Appoints Richard Beckman M.D. as Chief Medical Officer

Adverum Biotechnologies, Inc. Grants Orphan Drug Designation by FDA for Gene Therapy Candidate in Preclinical Development for the Treatment of Blue Cone Monochromacy

Adverum Biotechnologies Provides ADVM-022 Development Update and Anticipated Corporate Milestones for 2022

Independent Director recently sold US$109k worth of stock

Chief Business Officer & Acting CFO Christopher DeRespino has left the company

Adverum Biotechnologies, Inc. Provides Update on ADVM-022 and the INFINITY Trial in Patients with Diabetic Macular Edema

Adverum Biotechnologies, Inc.(NasdaqGM:ADVM) dropped from Russell 3000E Growth Index

Independent Chairman recently bought US$99k worth of stock

Lexeo Therapeutics, LLC Announces License Agreement with Adverum Biotechnologies, Inc

Adverum Biotechnologies, Inc. Appoints Reed V. Tuckson as an Independent Member to Board of Directors

Adverum Biotechnologies, Inc. Appoints Christopher J. Derespino as Chief Business Officer

Adverum Biotechnologies, Inc. Appoints Leone Patterson as Principal Financial Officer and Principal Accounting Officer

Independent Chairman recently bought US$115k worth of stock

Adverum Biotechnologies Completes Patient Enrollment for INFINITY Phase 2 Trial of ADVM-022 in DME

Adverum Biotechnologies, Inc Appoints Dawn Svoronos as Independent Member of Board of Directors

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Adverum Biotechnologies, Inc.

65.4x

-2.0x

Beneficios e Ingresos